Tocilizumab, an Exploratory Treatment for Severe COVID-19 Patients

Table 3

The CRP levels of COVID-19 patients before and after TCZ treatment (mg/L).

Case no.	Before TCZ therapy	After TCZ therapy							Clinical outcomes
		Day 1	Day 2	Day 3	Day 4	Day 5	Day 6	Day 7
1	25.32	17.69	11.52						Death
2	96.24	51.9	25.54	11.56	5.9			0.75	Clinical improvement
3	33.58		10.62		2.87			0.5	Clinical improvement
4	2.94	1.76			0.5				Clinical improvement
5	72.8	46.78			7.01		1.11		Clinical improvement
6	13.66	7.91				1.30		0.5	Clinical improvement
7	31.95	82.93		18.10				0.5	Clinical improvement
8	44.97	42.27				6.01		0.5	Clinical improvement
9	3.56			2.51					Clinical improvement
10	49.5		57.15	32.89					Death
11	6.25	9.59						0.5	Clinical improvement
12	10.82				2.17				Clinical improvement
13	63.76	40.94		0.5	6.92		0.5	0.5	Clinical aggravation

The normal value of CRP ranges from 0.00 to 10.00 mg/L.